Preliminary Evaluation of the Diagnostic Usefulness of Uroplakin 2 with an Assessment of the Antioxidant Potential of Patients with Bladder Cancer

. 2018 Nov 29;2018:8693297. doi: 10.1155/2018/8693297

(a) UP2 level in the plasma in BC patients and control group

Groups	UP2			p-value
	in plasma [ng/mL]			p-value
	Me	Mean	SD	in plasma
BC	3.65	3.71	1.29	p≤0.001 BC vs C
C	2.63	2.72	0.68	p≤0.001 BC vs C

NMIBC	3.55	3.73	1.40	p=0.650 NMIBC vsMIBC
NMIBC	3.55	3.73	1.40	p≤0.001 NMIBC vs C
MIBC	3.45	3.64	0.90	p≤0.001 NMIBC vs C
MIBC	3.45	3.64	0.90	p=0.003 MIBC vs C

LG	3.43	3.60	1.20	p=0.789 LG vs HG
LG	3.43	3.60	1.20	p≤0.001 LG vs C
HG	3.47	3.83	1.39	p≤0.001 LG vs C
HG	3.47	3.83	1.39	p≤0.001 HG vs C

M	3.65	3.87	1.34	p≤0.001 M vs W
W	2.97	2.89	0.48	p≤0.001 M vs W

Non-smoking BC	3.46	3.93	1.98	p=0.659 non-smoking BC vs smoking BC
Smoking BC	3.25	3.66	1.11	p=0.659 non-smoking BC vs smoking BC

UP2: uroplakin 2; BC: patients group; C: control group; NMIBC: non-muscle invasive BC; MIBC: muscle invasive BC; LG: low grade; HG: high grade; M: men; W: women; SD: standard deviation; p: statistically significant difference; Me: median.